Immunovia successfully develops assays to measure targeted proteins for its next-generation pancreatic cancer test – moving forward towards model-development study
LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the diagnostics company with the mission to increase pancreatic cancer survival rates through early detection, announces today that the company has successfully developed accurate and precise assays to measure targeted proteins for its next-generation test. As announced in November 2023 , Immunovia successfully finalized a discovery study that evaluated nearly 3,000 proteins to identify 15 promising protein